Abstract

Prognostic biomarkers that can reliably predict the disease-free survival (DFS) of locally advanced cervical cancer (LACC) are needed for identifying those patients at high risk for progression, who may benefit from a more aggressive treatment. In the present study, we aimed to construct a multiparametric MRI-derived radiomic signature for predicting DFS of LACC patients who underwent concurrent chemoradiotherapy (CCRT).MethodsThis multicenter retrospective study recruited 263 patients with International Federation of Gynecology and Obetrics (FIGO) stage IB-IVA treated with CCRT for whom pretreatment MRI scans were performed. They were randomly divided into two groups: primary cohort (n = 178) and validation cohort (n = 85). The LASSO regression and Cox proportional hazard regression were conducted to construct the radiomic signature (RS). According to the cutoff of the RS value, patients were dichotomized into low- and high-risk groups. Pearson’s correlation and Kaplan–Meier analysis were conducted to evaluate the association between the RS and DFS. The RS, the clinical model incorporating FIGO stage and lymph node metastasis by the multivariate Cox proportional hazard model, and a combined model incorporating RS and clinical model were constructed to estimate DFS individually.ResultsThe final radiomic signature consisted of four radiomic features: T2W_wavelet-LH_ glszm_Size Zone NonUniformity, ADC_wavelet-HL-first order_ Median, ADC_wavelet-HH-glrlm_Long Run Low Gray Level Emphasis, and ADC_wavelet _LL_gldm_Large Dependence High Gray Emphasis. Higher RS was significantly associated with worse DFS in the primary and validation cohorts (both p<0.001). The RS demonstrated better prognostic performance in predicting DFS than the clinical model in both cohorts (C-index, 0.736–0.758 for RS, and 0.603–0.649 for clinical model). However, the combined model showed no significant improvement (C-index, 0.648, 95% CI, 0.571–0.685).ConclusionsThe present study indicated that the multiparametric MRI-derived radiomic signature could be used as a non-invasive prognostic tool for predicting DFS in LACC patients.

Highlights

  • Cervical cancer is one of the most frequent malignancies in women, with over 604,000 new cases annually worldwide, associated with 342,000 deaths in 2020 [1]

  • The final radiomic signature consisted of four radiomic features: T2W_wavelet-LH_glszm_Size Zone NonUniformity, ADC_wavelet-HL-first order_Median, ADC_wavelet-HH-glrlm_Long Run Low Gray Level Emphasis, and ADC_wavelet _LL_gldm_Large Dependence High Gray Emphasis

  • The present study indicated that the multiparametric Magnetic resonance imaging (MRI)-derived radiomic signature could be used as a non-invasive prognostic tool for predicting disease-free survival (DFS) in locally advanced cervical cancer (LACC) patients

Read more

Summary

Introduction

Cervical cancer is one of the most frequent malignancies in women, with over 604,000 new cases annually worldwide, associated with 342,000 deaths in 2020 [1]. For patients diagnosed with locally advanced cervical cancer (LACC), concurrent chemoradiotherapy (CCRT) including pelvic external beam radiotherapy (EBRT), cisplatin-based chemotherapy, and brachytherapy, was the primary choice. Usual clinical features and standard exploitation of imaging fail to deliver actionable predictive models with sufficient accuracy in cervical cancer [3, 4]. Magnetic resonance imaging (MRI) is recognized as the firstline image modality for diagnosing, staging, treatment planning, treatment response evaluating, and monitoring during the whole process for LACC patients [5, 6]. For early-stage cervical cancer patients who underwent radical hysterectomy, radiomic features could predict patients’ survival with high accuracy [10]. Whether the multiparametric MRI-derived radiomic features could be used to predict survival in LACC patients underwent CCRT remains uncertain

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call